Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Jan 13, 2017 4:15pm

213 Views

Post# 25706441

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Time to get serious about this company

GV,

I took a look back on ClinicalTrials.gov for the ASSURE trial. From what is described, plaque regression in the RVX-208 vs. baseline was the primary outcome/endpoint. Comparisons of RVX-208 vs. placebo were secondary outcomes/endpoints.

The best result would have been RVX-208 showing significant plaque reduction against BOTH the RVX-208 baseline measurements AND compared to the placebo group. As we know, it didn't reach either goal. Hypothetically, if ASSURE did meet the primary goal of showing plaque regression against the RVX-208 baseline measure, but NOT against placebo.....I'm not sure how that mixed results would have been received.

BearDownAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale